Sunshine Biopharma Debt-to-Equity Ratio Growth & History (SBFM)

Sunshine Biopharma's debt-to-equity ratio was 0.04 for fiscal 2025.

View full Sunshine Biopharma company overview

Sunshine Biopharma annual debt-to-equity ratio history

Sunshine Biopharma annual debt-to-equity ratio

Fiscal yearPeriod endedDebt-to-equity ratioChangeGrowth
20252025-12-310.04−0.01−12.99%
20242024-12-310.040.01+30.69%
20232023-12-310.03−0.00−12.35%
20222022-12-310.040.04
20212021-12-310.00

Sunshine Biopharma debt-to-equity ratio trends

Between the periods ended 2021-12-31 and 2025-12-31, Sunshine Biopharma's debt-to-equity ratio increased from 0.00 to 0.04, a change of 0.04. The latest reported quarter, Q2 2026, shows 0.02.

About the metric

What the debt-to-equity ratio means

The debt-to-equity ratio compares interest-bearing debt with shareholders’ equity. It helps show how much debt financing a company uses relative to its accounting equity, but useful comparison levels vary by industry.

Calculation and source

How debt-to-equity is calculated

TickerStat calculates debt-to-equity as total interest-bearing debt divided by SEC-reported shareholders’ equity for the same balance-sheet date. Total liabilities are not treated as debt, and periods with non-positive equity are omitted. Fiscal periods can differ from calendar years, so exact period-end dates are included.

Review Sunshine Biopharma source filings ↗

Community posts

It’s quiet here.

No posts about SBFM yet. Start the conversation.

Write the first post